Discussion
We estimated absolute numbers of MSM using PrEP and their regional distribution in Germany between November 2017 and June 2020. Based on drug prescription data and self-reported PrEP use, the number of PrEP users in Germany during this period increased more than tenfold, but over time the increase appears to slow down. After an initial rapid increase in the number of PrEP users when affordable generics became available, we see a short phase of levelling off, and a second phase of rapid increase after PrEP, including associated tests, became reimbursable by statutory health insurance in Germany. The second rapid increase phase suggests that statutory health insurance reimbursement successfully removed an important PrEP access barrier. In 2020 we observed a second levelling-off of the increase, probably explained by behavioural adaptation to the SARS-CoV-2 (Coronavirus) pandemic, and in some areas probably also PrEP demand having been satisfied. Unfortunately, only sparse data on sexual behaviour of German MSM during the SARS-CoV-2 pandemic in 2020 is available. A PlanetRomeo survey from early April 2020 (during the first country-wide lockdown) with approximately 36,000 respondents from Germany showed dramatic reductions of sexual activity with non-steady partners (Planet Romeo
2020). A small survey among PrEP users conducted on Facebook in May 2020 showed reductions of daily PrEP use and increased on-demand use, likely reflecting a reduction of partner numbers (Robert Koch-Institut
2020).
Validity of assumptions
We focus now on the validity of the assumptions used for the two scenarios to estimate the total number of PrEP users in Germany:
For both scenarios we would like to discuss primarily the validity of the (PrApp-Survey-derived) proportions of on-demand/intermittent use and the validity of the regional distribution, particularly the proportion of PrEP users from Berlin. To estimate proportions of on-demand/intermittent use and regional distribution of PrEP users, we used data on PrEP use from three consecutive online surveys among MSM in Germany. In general, health and sexual behaviour online surveys among MSM such as EMIS-2017 provide reliable data on proportional regional and age distribution (Marcus et al.
2009; Scholz et al.
2019). However, mono-thematic online surveys (such as the PrApp-Surveys) may be affected by more unpredictable participation biases, determined by (for example) unmet needs. Robust evidence for a large online survey participation bias are the very similar proportions of EMIS-2017 respondents and PlanetRomeo user profiles indicating PrEP use in November 2017 and June 2020, despite the more than tenfold increase of PrEP users (see supplemental Table
S4). We tried to calibrate online survey data with PrEP use and prescription data from other sources. From these calibrations, we can conclude that self-selection biases for PrEP users to participate in online surveys can be very high and can vary considerably between surveys, depending probably on various factors such as framing of the survey, recruitment methods and advertising of the survey, perceived relevance to individuals, community mobilisation around PrEP access, and competing social and health issues. In our experience, the proportion of estimated PrEP users in Germany participating in online surveys varied between 37% in 2017 and 6% of all MSM actually using PrEP in 2020 (see Table
1). The low participation rate in spring 2020 is probably explained by a reduced intensity of recruitment activities, the coincidence with Coronavirus lockdowns and the overwhelming dominance of the Coronavirus pandemic in public perception and discourse. It is thus conceivable that participation biases could also affect the proportions of on-demand/intermittent PrEP use reported, and differ between regions with high satisfied demand and easy access to PrEP such as Berlin, and regions with higher access barriers. This could result in disproportional lower participation of PrEP users from Berlin in the PrApp-Surveys, as well as disproportional lower participation of on-demand/intermittent PrEP users in the consecutive PrApp-Survey rounds.
The participation bias in Berlin would reduce the discrepancy between the PrApp-Survey-derived PrEP user proportion and the prescription-derived distribution, and would thus be more consistent with the alternative explanations for these discrepancies.
To assess the plausibility of scenario 2, we have to discuss primarily the probability that the total number of PrEP users exceeds the estimate of scenario 1 as suggested by the calculated number of PrEP user profiles on PlanetRomeo. While the number of PlanetRomeo profiles indicating PrEP use is almost identical to the estimate of scenario 1, this coincidence fails to consider that — as outlined above — a proportion of 30% of PrEP users does not include PrEP use information in their online profiles. However, we must consider that a relevant proportion of PrEP profiles might belong to men already diagnosed with HIV who prefer to state in their profile that they take antiretroviral drugs for prevention rather than for treatment. Taking these two pieces of information into account, the PrEP profile number on PlanetRomeo supports that there are approximately 17,400 current PrEP users among MSM in Germany, a number that falls between our scenario 1 and 2 estimates. This number could be even higher if we consider that not all PrEP users may have a profile on PlanetRomeo. Furthermore, abandoned profiles, people creating multiple profiles, and former PrEP users not updating their profile information could lead to an overestimation of PrEP use based on the number of online profiles.
Regional distribution of PrEP users
Our regional distribution estimates reveal a distinct discrepancy with regard to the number and proportion of PrEP users in Berlin between different data sources, most pronounced between PrApp-Survey data and statutory health insurance data on prescriptions.
In the prescription data, prescriptions are allocated to the geographical area of the prescribing care provider. This results in well-known geographical biases for HIV drug prescription data, since people living in rural and underserved areas usually attend HIV specialists in urban centres for HIV treatment or PrEP prescription. This bias is particularly pronounced in the prescription data for Berlin and Hamburg where the number of prescriptions is thus higher, and is reversed in the surrounding federal states of Schleswig-Holstein, Lower Saxony, Mecklenburg-Western Pomerania, Brandenburg, Saxony-Anhalt, and Thuringia. However, if we assume that the discrepancy between the proportion of PrEP users in the PrApp-Survey and the prescription data is fully explained by this bias, we would have to assume large shifts from other federal states to Berlin to obtain prescriptions there. This is not impossible, but, given its magnitude, appears implausible. We find it more plausible to account for this difference between the PrApp-Survey and prescription data-derived regional distribution for Berlin by a combination of drug prescription shift to Berlin and a disproportional self-selection bias of PrEP users from Berlin in the PrApp-Survey. This could be the case if we assume that the comparatively high levels of satisfied PrEP need reached in Berlin would negatively impact the participation rate in a mono-thematic PrEP-focussed survey.
Thus, we believe it is likely that neither prescription data nor the PrApp-survey data represent the proportion of PrEP users living in Berlin correctly. The proportions observed in the PlanetRomeo PrEP profiles might be closer to the real distribution than PrApp-Survey and drug prescription data, as long as we can safely assume that PrEP profiles of men already diagnosed with HIV do not introduce a specific regional bias. PrEPuser profiles on GayRomeo represent a larger fraction of PrEP users in Germany than PrApp survey samples; the limitations inherent in the distribution of regional prescription data have been discussed. If any, one could assume that reporting PrEP use instead of treatment might be preferred in areas with higher levels of HIV-associated stigma, i.e., outside large cities, thus further increasing — rather than reducing — the regional inequalities that we identified.
Another possible reason for unreliability of regional distribution of drug prescription data is the inability to distinguish between prescriptions for HIV treatment and prescriptions for PrEP use. As described above, we designated excess prescriptions of TDF/FTC from the third quarter 2019 onwards — assuming no relevant changes in the amount of TDF/FTC used for HIV treatment — as PrEP prescriptions. If TDF/FTC use in HIV treatment developed differently in some regions, this would affect the regional distribution.
Self-selection biases
If our assumptions on self-selection biases are correct, different self-selection biases in countries with different social and political contexts must be considered for multi-country surveys such as EMIS-2017, which would have consequences for comparability of estimates for PrEP use and PrEP needs across countries (Hayes et al.
2019).
It is also difficult to estimate the self-selection biases for survey participants intending to use PrEP or “in need of PrEP” based on number of reported sex or CAI partners in the last 12 months. There are indications that sexual activity is an important factor contributing not only to perceived PrEP need, but also to self-selection for survey participation, suggesting that higher sexual activity is associated with a higher probability for survey participation. One aspect of this self-selection is the probability of seeing a survey recruitment message on a dating app. One of the apps we used for recruitment broadcasted each survey advertisement only for a period of 24 h. That means that frequent app users would have had a higher likelihood to see this message than infrequent users. This needs to be considered when extrapolating absolute numbers of PrEP users, intentional PrEP users, and men “in need of PrEP” based on their sexual risks, to the total MSM population of a country from proportions found in online surveys. In addition, other observations on the EMIS data suggest self-selection biases with increased sexual activity: e.g., the comparison of self-reported syphilis diagnoses in the last 12 months with syphilis cases among MSM reported to the German infectious disease surveillance system suggests a threefold higher probability that men diagnosed with syphilis had participated in the survey compared to a random distribution [personal communication by Ulrich Marcus and Susi Schink]. In the absence of an established method to estimate survey participation biases, the estimates based on sexual activity we chose are arbitrary, yet plausible. For this reason, we reported ranges with a minimum and a maximum estimated number.
A sizeable fraction of MSM indicated an intention to use PrEP if PrEP were available and affordable in a country, but did not report sexual risks defined as two or more non-steady CAI partners in the previous 12 months. These may be men who have been able to effectively manage risks, e.g., by using condoms, but who would consider switching to PrEP use as an alternative or additional risk management strategy if PrEP became available to them. Due to this group of men who would consider using PrEP, but who have also been able to manage their HIV risks effectively by using condoms, it is inherently difficult to estimate PrEP needs. We can show that this group of men with PrEP use intention and low risk reported in the past is not very different in terms of sexual partner numbers and HIV test uptake from the large group of men with no PrEP use intention and low reported risk (see Fig.
S1). The groups with intention to use PrEP differ from the groups not intending to use PrEP by a slightly higher awareness of PrEP (see Table
S4). How many of the men will use PrEP will likely depend on circumstances such as how convenient access to and monitoring of PrEP is, how PrEP use is advertised, how PrEP use is perceived by the gay community, how people assess risks and adverse effects of PrEP use for themselves, how satisfied these men are with the quantity and quality of the sex they have, and their expectations as to how this would change if they take PrEP. In addition, the size of this group may increase as PrEP knowledge and awareness is increasing in the MSM population.
PrEP need estimates
With our approach to estimate PrEP needs in Germany, we arrive at estimates of approximately 52,000 (variant 2) to 66,000 (variant 1) MSM currently in need of PrEP, of which approximately 16,000 (scenario 1) to 22,000 (scenario 2) were taking PrEP as of June 2020. The estimated number of PrEP need is close to the actual estimated number of MSM diagnosed with HIV in Germany (an der Heiden et al.
2019) and would be equivalent to 7.5% of the estimated total MSM population aged 18–65 years old, or 15% of the openly gay population aged 18–65 years old.
The proportion of MSM with intention to use PrEP in 2017 that is using PrEP in 2020 may vary between approximately 63% and 88% in Berlin (or even up to 104% if we use the regional distribution of PlanetRomeo PrEP profiles, which would mean that a larger proportion of people took PrEP in Berlin in June 2020 than people indicating PrEP use intention in 2017) and is below or around 20% in the federal states with the lowest coverage. This suggests marked regional differences and persistent barriers to access PrEP for people who intend to use PrEP.
One possible barrier after costs were covered by health insurance would be limited access to health-care providers licensed to prescribe PrEP covered by health insurance, either due to geographic distance, limited number of prescribers, or inconvenience associated with scheduling an appointment, or due to individual barriers such as fear to discuss safer sex or sex in general with a health-care provider, or lack of perceived social support for taking PrEP (Mayer et al.
2020). The strong correlation between satisfied PrEP needs and number of HIV specialists per 10,000 gay men practicing in the respective federal state suggests that easy access to PrEP prescribers has indeed a large impact on meeting the needs of potential PrEP users.
For MSM in Germany, taking up PrEP requires outing oneself towards a health-care provider, just as for other medical interventions such as HIV testing. Thus, factors identified as barriers to uptake of regular HIV testing among MSM in Germany such as problems identifying and making appointments with a gay-friendly health-care service, not feeling comfortable with being out about their own sexual orientation towards friends, family members, and co-workers, or not feeling at risk of HIV infection due to perceived familiarity with sex partners will likely play a similar role for PrEP uptake (Marcus et al.
2016). In particular, the problem of identifying and making appointments with a gay-friendly health-care service is likely to play a major role, since the number of services providing PrEP prescriptions is much smaller than the number of services providing HIV testing. This assumption is supported by the strong correlation between satisfied PrEP needs and number of HIV specialists at federal state level. This correlation is exacerbated by the practical difficulties of getting PrEP prescriptions that are experienced by men not living in or near the largest cities where most of the HIV specialists practice. While the skewed geographical distribution of HIV specialists appears to have no major impact on access to treatment for HIV, this skewed distribution still appears to be a major barrier for accessing drugs for prophylaxis. This assumption regarding PrEP uptake in Germany is supported by a similar analysis of the French EMIS-2017 dataset which concludes: “(PrEP-)Eligible MSM who are not using PrEP are mostly younger, […] living in small cities, […] and more distant from preventive health care and information than PrEP users. Despite free PrEP availability in France, results suggest that PrEP is not fully accessible and that there is a need to increase PrEP demand and decentralize PrEP delivery” (Annequin et al.
2020).
If we consider MSM who might benefit from but are currently not taking PrEP, a proportion of almost 50% of them may not have had an intention to use PrEP when asked in 2017. For informed decision-making, these men may need balanced and targeted information on PrEP. They may benefit from being offered PrEP proactively and from opportunities to discuss advantages and disadvantages of taking PrEP. This would require a proactive approach including sexual history taking by health-care providers and HIV test counsellors to actively provide this information, and might encourage demand by MSM who might probably benefit from PrEP.
Limitations
There are several limitations to our data sources and consequently to our analysis: the self-selection bias of men intending to use PrEP if available and affordable to participate in online surveys is unknown, and our attempts to estimate this bias may be biased by halo effects. When estimating met and unmet needs for PrEP, we combine data collected by the end of 2017 with data collected in 2020. The population indicating intention to use PrEP may have changed during this time due to increased awareness of and empirical experience with PrEP use. Grouping survey participants based on reported sexual risks such as CAI is subject to recall and social desirability biases.
The extent and number of individuals with on-demand/intermittent PrEP use is difficult to estimate based on our data. The PrApp-Surveys asked for the number of pills taken per month in categories (e.g., 1–11 pills/month) and in months when PrEP was used, not collecting information on the frequency and duration of PrEP use episodes. As these parameters remain unknown, the number of intermittent or on-demand PrEP users that can be supported by a full monthly PrEP dose remains uncertain. To address this uncertainty, we calculated the impact of different assumptions in our sensitivity analyses.
Acknowledgements
We thank all EMIS-2017 study participants and collaborators for being part of something huge. EMIS-2017 was coordinated by Sigma Research at the London School of Hygiene and Tropical Medicine (LSHTM) in association with the Robert Koch Institute (RKI) in Berlin. The following list acknowledges all partners in EMIS by country (using 2-letter IBAN country abbreviation). Individual names are mentioned if a freelancer was the main contact and/or translator or where input on the questionnaire development came from a person not formally representing an organisation. The order (if available) is main NGO partner, other NGO partners, academic partners, governmental partners, individuals.
Europe: PlanetRomeo, European AIDS Treatment Group (EATG), Eurasian Coalition on Male Health (ECOM), European Centre for Disease Prevention and Control (ECDC), European Monitoring Centre for Drugs & Drug Addiction (EMCDDA), European Commission (DG SANTE).
AL: Arian Boci.
AT: Aids Hilfe Wien, Dr. Frank M. Amort.
BA: lgbti.ba, Masha Durkalić.
BE: SENSOA, exaequo, Observatoire du SIDA et des sexualités, Sciensano.
BG: HUGE, GLAS Foundation, Dr. Emilia Naseva, Petar Tsintsarski.
BY: Vstrecha.
CA: Health Initiative for Men, Rézo, Gay Men’s Sexual Health Alliance of Ontario, CATIE, Ontario HIV Treatment Network, Université du Quebec & Montréal, University of Toronto, Ryerson University, University of Windsor, University of Victoria, Public Health Agency of Canada, Rob Gair.
CH: Swiss AIDS Federation, Cantonal Hospital St. Gallen, Centre Hospitalier Universitaire Vaudois, University Hospital Zurich, Swiss Federal Office of Public Health.
CY: AIDS Solidarity Movement.
CZ: AIDS pomoc, National Institute of Public Health, Tereza Zvolska, Dr. Michal Pitoňák.
DE: Deutsche AIDS-Hilfe, Robert Koch Institute, BZgA, Dr. Michael Bochow, Dr. Richard Lemke.
DK: AIDS-Fondet, Statens Serum Institut, François Pinchon, Jakob Haff.
EE: Eesti LGBT, VEK LGBT, Estonia National Institute for Health Development, Dr. Kristi Rüütel.
ES: Stop Sida, CEEISCAT, Ministerio de Sanidad. FI: Positiiviset, Hivpoint, SeksiPertti, Trasek, National Institute for Health and Welfare.
FR: AIDES, Coalition PLUS, SexoSafe, Santé Publique France, INSERM.
GR: Ath Checkpoint, Thess Checkpoint; Positive Voice.
HR: Iskorak, gay.hr., Zoran Dominković, Vjeko Vacek.
HU: Háttér Society, Tamás Bereczky.
IE: Gay Health Network, Man2Man, HIV Ireland, Outhouse, GOSHH, Sexual Health Centre Cork, AIDSWEST, Gay Community News, Health Service Executive, Gay Men’s Health Service, Sexual Health and Crisis Pregnancy Programme, Health Protection Surveillance Centre.
IL: Israel AIDS Task Force, Israel Ministry of Health, Dr. Zohar Mor. IS: Samtökin’78.
IT: Arcigay, Fondazione LILA Milano ONLUS, University of Verona, Dr. Raffaele Lelleri.
LB: SIDC, Dr. Ismaël Maatouk.
LT: demetra, LGL, Gayline.
LV: Testpunkts, Baltic HIV Association, Dr. Antons Mozalevskis, Indra Linina.
MD: GENDERDOC-M. ME: Juventas. MK: Subversive Front, Dr. Kristefer Stojanovski.
MT: Malta LGBTIQ Rights Movement, Allied Rainbow Communities, Infectious Disease Prevention and Control Unit, Silvan Agius, Russel Sammut. NL: Results in Health, Maastricht University, Amsterdam Pink Panel, Soa Aids Nederland, Rutgers, Dr. Wim Vanden Berghe, Marije Veenstra.
NO: Helseutvalget, Norwegian Directorate of Health, Folkehelseinstituttet, Dr. Rigmor C. Berg.
PH: Bisdak Pride-Cebu, Cebu Plus, HASH, Pinoy Plus, UP Babaylanes, YPEER, TLF, Office of the WHO Representative in the Philippines, Natasha Montevirgen, Mikael N. Navarro. PL: Spoleczny Komitet ds AIDS, Kampania Przeciw Homofobii, Lambda Warszawa, Dr. Łukasz Henszel.
PT: GAT Portugal, CheckpointLX, Associação ABRAÇO, rede ex aequo, SexED, dezanove, ILGA Portugal, Trombeta Bath, ISPUP.
RO: Association “Eu sunt! Tu?”, PSI Romania, ARAS Romania, Tudor Kovacs.
RS: Association Duga, Association Red Line, Omladina JAZAS-a Novi Sad, Institute of Public Health of Serbia, Sladjana Baros, Dr. Marija Pantelic.
RU: The Charity Foundation For Support of Social Initiatives and Public Health/LaSky Project.
SE: RFSL, University of Gothenburg, Folkhålsomyndigheten.
SI: ŠKUC, Legebitra, LJUDMILA. SK: PRIDE Košice, Light-House Slovakia, Slovak Medical University, Public Health Authority of the Slovak Republic, Dr. Zuzana Klocháňová. TR: Pozitif Yaşam, Sami S. Yazıcılaroğlu.
UA: Alliance for Public Health, alliance.global,
msmua.org, Oleksii Shestakovskyi.
UK: Terrence Higgins Trust, NAM, PrEPster, Antidote, Horizon Drugs and Alcohol Support, LGBT Foundation, Yorkshire MESMAC, MESMAC Newcastle, Derbyshire LGBT+, Trade Sexual Health, London Friend, GMFA, Spectra, International HIV Partnerships, International Planned Parenthood Federation, Bristol University, University College London, Sigma Research, Raul Soriano.
Other: Dr. John Pachankis, Dr. Mark Hatzenbühler, Dr. Valeria Stuardo Ávila, Dr. Michael W. Ross.
We thank all the participants of the PrApp-Survey. We also thank the app providers from Grindr, PlanetRomeo, and Hornet, the website prepjetzt.de, and the participating anonymous testing sites for their support in recruiting the participants. We thank S. Arslan, B. Augustin, S. Boender, V. Briesemeister, A. Gamroth, M. Gassowski, B. Haboub, I. Markus, S. Marzogoui, L. Meurs, O. Panochenko, A. Pantke, E. Romo-Ventura, N. Saad, G. Sarganas Margolis, E. Willems, and T. Yilmaz for their support with translations.
We thank Emmanuel Danan for sharing the results of his survey on Facebook among PrEP users.
We thank Franziska Hartung for sharing results of the online survey from positive stimmen 2.0.